论文部分内容阅读
目的研究依达拉奉治疗大面积脑梗死疗效及安全性。方法采用随机对照试验,入组2008年8月-2011年8月急性大面积脑梗死患者70例,治疗组35例、对照组35例,两组基础治疗相同,治疗组给予依达拉奉30mg加入NS 100ml静滴,30min滴完,2次/d,共14d。两组患者治疗前、治疗后第7、14、28d进行临床神经功能缺损评分,并进行疗效比较。结果治疗后7d,治疗组死亡率显著低于对照组(19.51%Vs 30.76%,P<0.005);治疗后14d治疗组总有效率(0.486 Vs 0.371,P<0.005)及显效率(0.200 Vs 0.114,P<0.005)均显著高于对照组,而且死亡率(24.39%Vs 38.46%,P<0.005)更低;治疗后28d治疗组总有效率(0.629 Vs 0.457,P<0.005)及显效率(0.343 Vs 0.200,P<0.005)均显著高于对照组,死亡率(26.82%Vs 43.58%,P<0.005)显著低于对照组;治疗组不良反应发生率为5.72%,对照组为0.00%,两组比较无明显统计学意义。结论依达拉奉治疗急性期大面积脑梗死疗效显著,安全性高。
Objective To study the efficacy and safety of edaravone in treating large area cerebral infarction. Methods A randomized controlled trial was conducted in 70 patients with acute large-area cerebral infarction from August 2008 to August 2011, 35 patients in the treatment group and 35 patients in the control group. The two groups had the same basic treatment. The patients in the treatment group received edaravone 30mg Add NS 100ml intravenous drip, 30min drip finished, 2 times / d, a total of 14d. Two groups of patients before treatment, 7,14,28 d after treatment of clinical neurological deficit score, and the efficacy comparison. Results After 7 days of treatment, the mortality of the treatment group was significantly lower than that of the control group (19.51% Vs 30.76%, P <0.005); after 14 days of treatment, the total effective rate (0.486 Vs 0.371, P <0.005) , P <0.005) were significantly higher than those in the control group, and the mortality rate was lower (24.39% vs 38.46%, P <0.005). The total effective rate (0.629 Vs 0.457, P <0.005) and the effective rate 0.343 Vs 0.200, P <0.005) were significantly higher than the control group, the mortality rate (26.82% Vs 43.58%, P <0.005) was significantly lower than the control group; the incidence of adverse reactions in the treatment group was 5.72%, 0.00% No significant difference between the two groups was statistically significant. Conclusion Edaravone treatment of acute cerebral infarction significant effect, high safety.